52 Week Range
As of on the Virt-X ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Biontech Says Request For COVID-19 Vaccine Approval Could Be Filed End Of Oct.
European Medicines Agency Approves Safety Label Update For Novartis Beovu
Novartis: planning to appeal against French watchdog's decision to fine it
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Independent Non-Executive Chairman of the Board
Honorary Chairman of the Board
Daniel L. Vasella
Honorary Chairman of the Board
Chief Executive Officer, Member of the Executive Committee
Independent Non-Executive Vice Chairman of the Board
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
BioNTech is buying a production site for the COVID-19 vaccine it is developing with Pfizer, aiming to boost output by several hundred million doses next year, and hopes to have the shot ready to file for approval in October.
A federal judge in Delaware on Wednesday dealt another setback to drug company Biogen Inc in its effort to keep generic versions of its multiple sclerosis treatment Tecfidera off the market through patent litigation.
Novartis raised 1.85 billion euros on Wednesday from the sale of a bond on which interest payments will rise if the drugmaker fails to expand access to medicines and programmes to combat malaria and leprosy in a number of developing countries.
Swiss drugmaker Roche on Monday said two-thirds of spinal muscular atrophy (SMA) patients now taking its newly approved drug Evrysdi have previously received rival treatments Zolgensma from Novartis or Biogen's Spinraza.
Novartis's Beovu matched Regeneron's Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said on Monday, after early safety stumbles for the medicine in another condition caused disappointing early sales.
Novartis on Monday said its eye drug Beovu matched rival Eylea from Regeneron in visual acuity at one year in patients with diabetic macular edema (DME), as the Swiss drugmaker seeks to regain momentum with the drug after early safety stumbles.
Switzerland's Novartis and Roche were fined 444 million euros (403.55 million pounds)by France, after its competition authority said on Wednesday they used abusive practices to push costly eye injection Lucentis over a cheaper drug.
Roche aims to defend its multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an experimental medicine, fenebrutinib.
Drugmaker Novartis on Tuesday announced new sustainability targets, including boosting access to its medicines and global outreach as well as aiming to make its supply chain carbon neutral by 2030.
Novartis drug candidate asciminib notched a trial win against Pfizer's Bosulif, the Swiss drugmaker said on Wednesday, as it pushes to expand medicines for chronic myeloid leukaemia in patients for whom other treatments stopped working.
Swiss drugmaker Novartis AG has financial firepower for acquisitions even with net debt of $26 billion, though the COVID-19 pandemic has made it more difficult to value takeover candidates, Chief Executive Vas Narasimhan said in an interview.
Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer.
Novartis on Thursday won U.S. Food and Drug Administration (FDA) approval to repurpose an 11-year-old blood cancer drug against multiple sclerosis as the Swiss drugmaker takes on rival Roche's big-selling Ocrevus for the autoimmune disorder.
A U.S. district court upheld the validity of a patent for Swiss drugmaker Novartis' top-selling multiple sclerosis (MS) drug Gilenya, helping Novartis protect its blockbuster MS treatment from U.S. competition.
Novartis CAR-T cell therapy Kymriah met its primary endpoint at an interim analysis of a phase-II trial in patients with relapsed or refractory follicular lymphoma, the Swiss drugmaker said on Tuesday.
Novartis has received European Union approval for its Cosentyx drug to be a standard treatment for psoriasis in children, the company said on Monday.
Novartis's sickle cell disease treatment Adakveo appears set for European approval after a key committee on Friday gave its backing to the drug that booked $36 million in first-half U.S. sales.
The former Novartis sales representative whose whistleblower lawsuit against the drugmaker led to a $678 million settlement with the federal government and various states earlier this year will receive an award of $109.4 million.
One of medicine's costliest treatment areas could become even more pricey as Biogen seeks to layer its $750,000 spinal muscular atrophy drug on top of $2.1 million-per-patient Novartis gene therapy Zolgensma.
Novartis Chief Executive Vas Narasimhan said spinal muscular atrophy patients who got the Swiss drugmaker's Zolgensma maintained improvements, a response to Biogen's plan to test its drug Spinraza after Zolgensma treatment.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.